New Isotope Production System at Bruce Power successfully produces first medical isotope скачать в хорошем качестве

New Isotope Production System at Bruce Power successfully produces first medical isotope

An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company), and ITM Isotope Technologies Munich SE (ITM), announced today a milestone marking the first instance lutetium-177, a short-lived medical isotope, has been produced in a commercial nuclear power reactor. Lutetium-177 is a medical isotope used in the treatment of various cancers, such as neuroendocrine tumours and prostate cancer. In the future, this system will also have the ability to produce other isotopes for medical uses. This milestone was achieved using a new Isotope Production System (IPS) that was installed in Bruce Power’s Unit 7 during a recent planned maintenance outage. The IPS is now ready for use in the commercial production of medical isotopes, pending final regulatory review and approval by the Canadian Nuclear Safety Commission (CNSC). Bruce Power will market the new isotope supply in an historic collaboration partnership with Saugeen Ojibway Nation (SON). The partnership project with SON, named Gamzook’aamin Aakoziwin, includes an equity stake for SON and a revenue-sharing program that provides a direct benefit to the community.